Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Low-Affinity Immunoglobulin E Receptor (CD23)
- Target
- CD23
- Molecular classification
- Type II transmembrane glycoprotein, C-type lectin, Receptor
01
Overview
CD23, the low-affinity IgE receptor (FcεRII), is a type II transmembrane glycoprotein that plays a crucial role in regulating IgE levels and mediating allergic responses. It is expressed on various immune cells, including B lymphocytes, macrophages, and eosinophils. CD23 binds to IgE and participates in antigen presentation, cell adhesion, and the modulation of immune signaling pathways. Due to its central role in allergic responses, CD23 is considered a promising target for therapeutic intervention strategies aimed at treating allergies or modulating humoral immunity.
- Other names
- Fc epsilon RIIFcεRIIBLAST-2FCER2IGEBF (IgE-binding factor)Lymphocyte IgE receptor
02
Mechanism of action
Targeting CD23 aims to disrupt IgE-mediated allergic responses and modulate humoral immunity.
03
Biological functions
Regulation of IgE levelsAntigen presentationCell adhesionImmune responseModulation of allergic responsesHumoral immune responses
04
Disease associations
AllergyAutoimmunityChronic inflammation
Beyond the preview
Go deeper on Low-Affinity Immunoglobulin E Receptor (CD23).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Low-Affinity Immunoglobulin E Receptor (CD23).